Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis.
Bond
A
A
Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, U.K.
Corlett
L
L
Nagvekar
N
N
Jacobson
L
L
Pantic
N
N
Beeson
D
D
Nicolle
M
M
Vincent
A
A
Newsom-Davis
J
J
Spack
E
E
Willcox
N
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001324:Autoantigens / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009045:Motor Endplate / Q000276:immunology / Q000502:physiology; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy; D009157:Myasthenia Gravis / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D011950:Receptors, Cholinergic / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D013945:Thymoma / Q000276:immunology; D013953:Thymus Neoplasms / Q000276:immunology
D000911:Antibodies, Monoclonal; D001324:Autoantigens; D011948:Receptors, Antigen, T-Cell; D011950:Receptors, Cholinergic; D011994:Recombinant Proteins